NanoString Technologies, Inc. (NASDAQ:NSTG) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
held its 2017 Annual Meeting of Stockholders (the Annual
Meeting). At the Annual Meeting, proxies representing 18,121,227
shares of the Companys common stock, or approximately 84% of the
total shares entitled to vote, were present and voted on the
following proposals, which are described in more detail in the
Companys definitive proxy statement filed with the United States
Securities and Exchange Commission (the SEC) on April 28, 2017:
nominees were each elected as a Class I director to serve until
the 2020 annual meeting of stockholders or until his successor is
duly elected and qualified.
|
Nominee
|
For
|
Withheld
|
Broker Non-Votes
|
|||
|
R. Bradley Gray
|
15,439,143
|
268,132
|
2,413,952
|
|||
|
Robert M. Hershberg, M.D., Ph.D.
|
15,438,370
|
268,905
|
2,413,952
|
|||
|
Kirk D. Malloy, Ph.D.
|
15,436,330
|
270,945
|
2,413,952
|
Registered Public Accounting Firm. The appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the Companys fiscal year ending
December 31, 2017 was ratified.
|
For
|
Against
|
Abstain
|
||
|
18,096,765
|
23,090
|
1,372
|
About NanoString Technologies, Inc. (NASDAQ:NSTG)
NanoString Technologies, Inc. develops and manufactures intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. It markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology, and to clinical laboratories and medical centers for diagnostic use. Its molecular diagnostic product Prosigna Breast Cancer Assay provides an assessment of a patient’s risk of recurrence for breast cancer.